Price$13.35-0.66 (-4.71%)
01:30 PM07:45 PM
News · 26 weeks73+533%
2026-01-252026-07-19
Mix4190d
- Insider20(49%)
- SEC Filings12(29%)
- Leadership4(10%)
- Other4(10%)
- Analyst1(2%)
Latest news
25 items- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor Conferences in JulyNEW YORK, July 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July:July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will participate in one-on-one investor meetings at this conference in Boston. To schedule a meeting, please contact your Leerink representative or Jessica Breu at:
- INSIDERSEC Form 4 filed by Director Skerjanec Simona4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Rudick Richard Alan4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Barclay A4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Neermann Joerg4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Congleton Jon4 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update8-K - IMMUNIC, INC. (0001280776) (Filer)
- INSIDERSEC Form 4 filed by Director Congleton Jon4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Skerjanec Simona4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Rudick Richard Alan4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Howson Tamar D4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Whaley Glenn4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Tardio Jason4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Neermann Joerg4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Barclay A4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Vitt Daniel4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Bonney Michael W4 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor, Industry and Scientific Conferences in JuneNEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. Erik Lundgren, Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat at this summit taking place in New York and virtually. The pre-recorded presentation will be available for registered attendees via the H.C. Wainwright conference site starting on Monday, Jun
- INSIDERSEC Form 4 filed by Chief Executive Officer Lundgren Erik4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lundgren Erik3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECSEC Form DEF 14A filed by Immunic Inc.DEF 14A - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –– Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood –NEW YORK, May 28, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-r
IMUX FAQ
7 questionsWhat does Immunic Inc. do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from...Where does IMUX stock trade?
Immunic Inc. (IMUX) is listed on NASDAQ.What sector and industry is IMUX in?
Immunic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunic Inc. go public?
Immunic Inc. (IMUX) completed its IPO in 2014.What are analysts saying about IMUX?
Immunic Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-05-22.What companies are similar to IMUX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMUX side-by-side with any of them on Quantisnow.How can I track IMUX on Quantisnow?
Quantisnow aggregates Immunic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMUX to receive live email and push alerts on every new disclosure.